Drug intelligence / Profile preview

RO5469754

Development stage: Phase 1
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

RO5469754 is a humanized monoclonal antibody developed by F. Hoffmann-La Roche. It acts as an antagonist of thymic stromal lymphopoietin (TSLP), a cytokine involved in the regulation of immune responses and inflammation. The drug has been investigated for intravenous and subcutaneous administration in healthy adults, with its highest global R&D status listed as pending. No FDA designation or approved indications are currently reported[1][2][3][7].

Targets

TSLP (Thymic stromal lymphopoietin)

Beyond the preview

Go deeper on RO5469754.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO5469754.

Explore the full profile